Humacyte Presents Potential of Functional Lung Engineering at Janelia R3 - Replace, Repair, Regenerate Planning Workshop
DURHAM, N.C., July 22, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announces that Laura Niklason, M.D., Ph.D., Chief Executive Officer, delivered an invited presentation on laboratory and preclinical findings and notable criteria for engineering functional air sacs in the lungs, which support the potential to create engineered lung tissue organ, at the virtual Janelia R3 – Replace, Repair, Regenerate Planning Workshop. Janelia is a Howard Hughes Medical Institute pioneering research center that empowers an integrated team of scientists to pursue a small number of scientific questions with the potential for transformative impact.
The laboratory and preclinical data presented at the Janelia R3 conference demonstrate that inter-individual variability in single-cell data is tolerable, and that it is possible to identify lung alveolar signaling patterns across wide phylogenetic ranges. The findings point to cell-to-cell communication in the alveolus, an important finding that may guide the future development of functional lung tissues.
“Engineering tissue for complex organs, such as whole lungs, is fraught with myriad challenges, including ascertaining a detailed understanding of how cells interact and communicate with one another,” said Dr. Niklason. “Humacyte’s universally implantable bioengineered tissue has the potential to be a transformative advancement for the field of regenerative medicine. These findings underscore key criteria and interactions to be considered when engineering functional lung alveoli, suggesting that cell-to-cell communication in the lung alveolus is critical, and support the foundation of our early stage whole lung development work based on our Human Acellular Vessels (HAV) platform.”
On February 17, 2021, Alpha Healthcare Acquisition Corp. (Nasdaq: AHAC) (“AHAC”), a special purpose acquisition company, and Humacyte announced the execution of a definitive business combination agreement along with a fully committed $175 million PIPE financing agreement.
About Alpha Healthcare Acquisition Corp.
Important Information About the Merger and Where to Find It
Participants in the Solicitation
Humacyte Investor Contact:
Humacyte Media Contact:
Raising the Bar for IoT Security with the Matter Standards
Orchestration Getting to the Single Pane of Glass
Presentation Details TBA